Lacutamab

Lacutamab (IPH4102) is a humanizedized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma[1].

Product Specifications

CAS Number

[2187368-16-5]

Product Name Alternative

IPH 4102; Anti-KIR3DL2/CD158k Reference Antibody (lacutamab)

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lacutamab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Lacutamab]

Molecular Weight

(144.52 kDa)

References & Citations

[1]Van Der Weyden C, et, al. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2018 Aug;27 (8) :691-697.